Ginkgo Bioworks Holdings (DNA) Research & Development (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Research & Development came in at $49.9 million in Q1 2026, down 29.61% YoY from $70.9 million in Q1 2025, and little changed on a QoQ basis from $50.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Research & Development (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Research & Development data on file, last reported at $49.9 million in Q1 2026.
- Quarterly Research & Development fell 29.61% year-over-year to $49.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222.8 million (down 37.87% YoY) and the FY2025 annual result came in at $243.8 million, down 42.51% from the prior year.
- Research & Development steadied at $49.9 million in Q1 2026, from $50.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $323.6 million in Q1 2022 to a low of $49.9 million in Q1 2026.
- A 5-year average of $138.3 million and a median of $134.2 million in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 457.47% in 2022, down 81.98% in 2022.
- Tracing DNA's Research & Development over 5 years: stood at $177.5 million in 2022, then plunged by 34.08% to $117.0 million in 2023, then slumped by 34.74% to $76.4 million in 2024, then tumbled by 34.37% to $50.1 million in 2025, then dropped by 0.41% to $49.9 million in 2026.
- The last three Research & Development figures came in at $49.9 million (Q1 2026), $50.1 million (Q4 2025), and $69.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 46.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.21 Mn |
| Mar 31, 2026 | 49.92 Mn |
| Dec 31, 2025 | 50.13 Mn |
| Sep 30, 2025 | 69.35 Mn |
| Jun 30, 2025 | 53.37 Mn |
| Mar 31, 2025 | 70.92 Mn |
| Dec 31, 2024 | 76.38 Mn |
| Sep 30, 2024 | 77.01 Mn |
| Jun 30, 2024 | 134.22 Mn |
| Mar 31, 2024 | 136.46 Mn |
| Dec 31, 2023 | 117.04 Mn |
| Sep 30, 2023 | 156.66 Mn |
| Jun 30, 2023 | 144.28 Mn |
| Mar 31, 2023 | 162.64 Mn |
| Dec 31, 2022 | 177.55 Mn |
| Sep 30, 2022 | 261.46 Mn |
| Jun 30, 2022 | 290.06 Mn |
| Mar 31, 2022 | 323.58 Mn |
| Dec 31, 2021 | 985.03 Mn |
| Sep 30, 2021 | 53.02 Mn |